The Guadeloupe, Saint-Martin and Saint-Barthélemy Health Agency authorizes the Guadeloupe University Hospital to use a new radio pharmaceutical drug used in particular for screening for prostate cancer.
The Director General of ARS grants an authorization to extend the activities of the Pharmacy for Internal Use (PUI) of CHUG. It will now be able to manufacture the tracer based on FLUOROCHOLINE. This medication will complement the range of radio pharmaceutical tracers used at the Guadeloupe Molecular Imaging Center (CIMGUA), thereby facilitating the monitoring of a greater diversity of cancers.
FLUOROCHOLINE constitutes an important advance in diagnostic matters because it reveals the presence of cancer cells not detected to date by the tracer used so far. This product will gradually improve the quality of screening and monitoring of patients, especially those affected by prostate cancer. Consequently, between 700 and 800 examinations per year can be carried out in our territory.
The Director General of ARS and the Director General of CHUG are delighted with the implementation of this new technique for the benefit of Guadeloupeans.
6,564 total views
No comments